Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Accumulated Expenses (2017 - 2025)

KalVista Pharmaceuticals' Accumulated Expenses history spans 11 years, with the latest figure at $27.3 million for Q2 2025.

  • On a quarterly basis, Accumulated Expenses rose 308.36% to $27.3 million in Q2 2025 year-over-year; TTM through Apr 2025 was $27.3 million, a 308.36% increase, with the full-year FY2025 number at $27.3 million, up 308.36% from a year prior.
  • Accumulated Expenses hit $27.3 million in Q2 2025 for KalVista Pharmaceuticals, up from $8.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for KALV hit a ceiling of $27.3 million in Q2 2025 and a floor of $2.5 million in Q3 2023.
  • Historically, Accumulated Expenses has averaged $8.0 million across 4 years, with a median of $6.7 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: rose 8.39% in 2021 and later soared 314.03% in 2024.
  • Tracing KALV's Accumulated Expenses over 4 years: stood at $6.9 million in 2021, then crashed by 44.4% to $3.9 million in 2023, then surged by 116.35% to $8.3 million in 2024, then soared by 227.58% to $27.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for KALV at $27.3 million in Q2 2025, $8.3 million in Q4 2024, and $7.0 million in Q4 2024.